Lead Product(s) : Raludotatug Deruxtecan
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2/3 of Raludotatug Deruxtecan Begins in Platinum-Resistant Ovarian Cancer Patients
Details : R-DXd (raludotatug deruxtecan) potential first-in-class CDH6 directed DXd antibody drug conjugate. It is being evaluated for the treatment of patients with platinum-resistant ovarian cancer.
Product Name : DS-6000a
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 04, 2024
Lead Product(s) : Raludotatug Deruxtecan
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The supplemental application for approval for Opdivo® has been filed based on the data from the following 2 clinical studies: CheckMate -649 study (ONO-4538-44) and ATTRACTION-4 study (ONO-4538-37.
Product Name : Opdivo
Product Type : Antibody
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable